For FY2026 Q3, net sales reached 1,183,158 million yen (1.8% YoY increase), operating income was 12,422 million yen (13.3% YoY decrease), and net income attributable to owners of parent for the quarter was 14,448 million yen (40.9% YoY increase).<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"8129","jir_company_name":"Toho Holdings Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2605","jir_publication_date":"2026-02-12","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/02\/8129-20260212-01.pdf","jir_short_summary":"For FY2026 Q3, net sales reached 1,183,158 million yen (1.8% YoY increase), operating income was 12,422 million yen (13.3% YoY decrease), and net income attributable to owners of parent for the quarter was 14,448 million yen (40.9% YoY increase).","jir_summary":"### Performance Overview\nThe consolidated results for FY2026 Q3 recorded net sales of 1,183,158 million yen (1.8% YoY increase), operating income of 12,422 million yen (13.3% YoY decrease), ordinary income of 14,168 million yen (11.7% YoY decrease), and net income attributable to owners of parent of 14,448 million yen (40.9% YoY increase). In the pharmaceutical wholesaling business, despite decreased demand for COVID-related products, net sales increased YoY due to expanded handling of specialty pharmaceuticals and enhanced customer support services. The dispensing pharmacy business achieved net sales of 75,394 million yen (4.4% YoY increase) and segment profit of 1,179 million yen (60.6% YoY increase), representing significant profit growth. The pharmaceutical manufacturing and sales business posted net sales of 8,750 million yen (1.0% YoY increase) and segment profit of 167 million yen (69.2% YoY decrease).\n\n### Financial Position and Dividend Status\nTotal assets stood at 826,097 million yen, up 14.3% from the previous consolidated fiscal year-end, and net assets increased by 4.7% to 268,939 million yen; however, the equity ratio declined from 35.5% to 32.5%. The annual dividend is planned at 120 yen (interim 45 yen, year-end 75 yen), a significant increase from 65 yen the previous year. Share buyback activities have also been conducted to improve capital efficiency and enhance shareholder returns.","jir_financial_highlights":"Net Sales: 1,183,158 million yen (1.8% YoY increase)\nOperating Income: 12,422 million yen (13.3% YoY decrease)\nOrdinary Income: 14,168 million yen (11.7% YoY decrease)\nNet Income Attributable to Owners of Parent: 14,448 million yen (40.9% YoY increase)\nTotal Assets: 826,097 million yen (14.3% increase from the previous consolidated fiscal year-end)\nNet Assets: 268,939 million yen (4.7% increase from the previous consolidated fiscal year-end)\nEquity Ratio: 32.5% (Decrease from 35.5% at the previous consolidated fiscal year-end to 32.5%)\nAnnual Dividend (Forecast): 120 yen (Increased from 65 yen last year)","jir_category":"","jir_hashtags":"#TohoHoldings, #FinancialSummary, #JapaneseStocks","jir_key_figures":"Net Sales: 1,183,158 million yen (1.8% YoY increase)\nOperating Income: 12,422 million yen (13.3% YoY decrease)\nNet Income Attributable to Owners of Parent: 14,448 million yen (40.9% YoY increase)","jir_meta_title":"Toho Holdings FY2026 Q3 Financial Summary: Net Sales 118.3 Billion Yen, Net Income Up 40.9%","jir_meta_description":"Toho Holdings Co., Ltd.'s FY2026 Q3 Financial Summary. Net sales of 1,183,158 million yen (1.8% YoY increase) and net income attributable to owners of parent of 14,448 million yen (40.9% YoY increase). Annual dividend forecast of 120 yen.","jir_og_title":"Toho Holdings FY2026 Q3 Financial Results Announcement","jir_og_description":"Achieved net sales of 118.3 billion yen and net income of 14,448 million yen (40.9% YoY increase). Dividend increase planned.","jir_og_image_url":"\/assets\/og\/company-financial_summary.jpg","jir_chart_data_collection":"[{\"jir_chart_id\": \"revenue_trend\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Net Sales Trend (Million Yen)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"FY2025 Q3 Cumulative\\\",\\\"FY2026 Q3 Cumulative\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Net Sales\\\",\\\"data\\\":[1162052,1183158],\\\"backgroundColor\\\":\\\"#4e79a7\\\"}]},\\\"options\\\":{\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}, {\"jir_chart_id\": \"operating_profit_trend\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Operating Income Trend (Million Yen)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"FY2025 Q3 Cumulative\\\",\\\"FY2026 Q3 Cumulative\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Operating Income\\\",\\\"data\\\":[14329,12422],\\\"backgroundColor\\\":\\\"#f28e2b\\\"}]},\\\"options\\\":{\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}, {\"jir_chart_id\": \"net_profit_trend\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Net Income Attributable to Owners of Parent Trend (Million Yen)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"FY2025 Q3 Cumulative\\\",\\\"FY2026 Q3 Cumulative\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Net Income\\\",\\\"data\\\":[10252,14448],\\\"backgroundColor\\\":\\\"#e15759\\\"}]},\\\"options\\\":{\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}, {\"jir_chart_id\": \"segment_revenue_breakdown\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Segment Net Sales Breakdown (Million Yen)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Pharmaceutical Wholesaling\\\",\\\"Dispensing Pharmacy\\\",\\\"Pharmaceutical Manufacturing and Sales\\\",\\\"Other Peripheral Businesses\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"FY2026 Q3 Cumulative\\\",\\\"data\\\":[1139827,75394,8750,5303],\\\"backgroundColor\\\":[\\\"#4e79a7\\\",\\\"#f28e2b\\\",\\\"#e15759\\\",\\\"#76b7b2\\\"]}]},\\\"options\\\":{\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}, {\"jir_chart_id\": \"segment_profit_breakdown\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Segment Profit (Operating Income) Breakdown (Million Yen)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Pharmaceutical Wholesaling\\\",\\\"Dispensing Pharmacy\\\",\\\"Pharmaceutical Manufacturing and Sales\\\",\\\"Other Peripheral Businesses\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"FY2026 Q3 Cumulative\\\",\\\"data\\\":[12309,1179,167,681],\\\"backgroundColor\\\":[\\\"#4e79a7\\\",\\\"#f28e2b\\\",\\\"#e15759\\\",\\\"#76b7b2\\\"]}]},\\\"options\\\":{\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}]","ir_related_company":8078,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-27666","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n